Institution
Charles University in Prague
Education•Prague, Czechia•
About: Charles University in Prague is a education organization based out in Prague, Czechia. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 32392 authors who have published 74435 publications receiving 1804208 citations.
Topics: Population, Large Hadron Collider, Czech, Magnetization, Transplantation
Papers published on a yearly basis
Papers
More filters
DOI•
07 Dec 2015
TL;DR: The FEniCS Project is a collaborative project for the development of innovative concepts and tools for automated scientific computing, with a particular focus on the solution of differential equations by finite element methods.
Abstract: The FEniCS Project is a collaborative project for the development of innovative concepts and tools for automated scientific computing, with a particular focus on the solution of differential equations by finite element methods. The FEniCS Projects software consists of a collection of interoperable software components, including DOLFIN, FFC, FIAT, Instant, UFC, UFL, and mshr. This note describes the new features and changes introduced in the release of FEniCS version 1.5.
1,628 citations
TL;DR: The European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (NMIBC) were published in 2013 and the levels of evidence and grades of recommendation were assigned.
1,608 citations
Population Health Research Institute1, Centra2, Charles University in Prague3, University of Washington Medical Center4, Brigham and Women's Hospital5, National University of Ireland, Galway6, University College London7, Jagiellonian University8, University of Würzburg9, Semmelweis University10, Karolinska Institutet11, University of the Philippines12, University of La Frontera13, University of Cape Town14, Aalborg University15, Katholieke Universiteit Leuven16, Catholic University of Korea17, Monash University18, Universiti Teknologi MARA19, Paris Diderot University20
TL;DR: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assign to aspirin alone.
Abstract: BackgroundWe evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. MethodsIn this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. ResultsThe primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1....
1,587 citations
TL;DR: Adalimumab was superior to placebo for induction of remission in patients with moderate to severe Crohn's disease naive to anti-TNF therapy and was well tolerated.
1,579 citations
TL;DR: The number of adults with raised blood pressure increased from 594 million in 1975 to 1·13 billion in 2015, with the increase largely in low-income and middle-income countries, and the contributions of changes in prevalence versus population growth and ageing to the increase.
1,573 citations
Authors
Showing all 32719 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Ronald C. Petersen | 178 | 1091 | 153067 |
| P. Chang | 170 | 2154 | 151783 |
| Vaclav Vrba | 141 | 1298 | 95671 |
| Milos Lokajicek | 139 | 1511 | 98888 |
| Christopher D. Manning | 138 | 499 | 147595 |
| Yves Sirois | 137 | 1334 | 95714 |
| Rupert Leitner | 136 | 1201 | 90597 |
| Gerald M. Reaven | 133 | 799 | 80351 |
| Roberto Sacchi | 132 | 1186 | 89012 |
| S. Errede | 132 | 1481 | 98663 |
| Mark Neubauer | 131 | 1252 | 89004 |
| Peter Kodys | 131 | 1262 | 85267 |
| Panos A Razis | 130 | 1287 | 90704 |
| Vit Vorobel | 130 | 919 | 79444 |
| Jehad Mousa | 130 | 1226 | 86564 |